Astrana is a profitable, scaled value-based care consolidator—if it executes the Prospect turnaround and reduces payer concentration, today’s discounted multiple could re-rate sharply.
Astrana Health Inc. (ASTH), formerly known as Apollo Medical Holdings, stands as a distinct entity in the rapidly evolving landscape of United States healthcare services. Headquartered in Alhambra, California, the company has positioned itself at the vanguard of the industry's structural transition from a fee-for-service (FFS) reimbursement model to value-based care (VBC). Unlike traditional healthcare providers that generate revenue based on the volume of services rendered—a model often criticized for incentivizing inefficiency and overutilization—Astrana operates on a population health management chassis. The company contracts with payers to assume financial responsibility for the total cost of care for patient populations, incentivizing the delivery of high-quality, preventative care that reduces expensive downstream utilization such as emergency room visits and hospital admissions.
The core of Astrana’s identity is its "payer-agnostic" and "physician-centric" philosophy. While many competitors in the VBC space, such as Kaiser Permanente, operate closed integrated delivery networks (IDNs) or, like Oak Street Health, rely heavily on employed staff models, Astrana aggregates independent physicians into a cohesive, technology-enabled network. This "enablement" model allows independent providers to participate in lucrative global risk contracts without the administrative burden or capital intensity of building their own managed care infrastructure. As of early 2026, Astrana serves over 10,000 providers and manages approximately 1.1 million patients across a diverse payer mix including Medicare, Medicaid, and Commercial insurance.
The fiscal years 2024 and 2025 represented a definitive inflection point in the company’s corporate history, primarily driven by the transformative acquisition of Prospect Health. This transaction was not merely a bolt-on expansion but a fundamental restructuring of the company’s scale and operational scope. As detailed in the Q3 2025 earnings release, the consolidation of Prospect Health’s assets propelled Astrana’s total revenue to $956.0 million for the quarter, a 100% increase from the $478.7 million reported in the same period of the prior year.
This acquisition served multiple strategic imperatives simultaneously. First, it provided immediate scale, doubling the company's topline revenue and significantly increasing the lives under management. Second, it offered a platform for "operational arbitrage." Prospect Health, while possessing valuable provider networks and patient panels, had historically underperformed in terms of medical margin management. Astrana’s investment thesis rests on the application of its proprietary CareOps technology platform to these newly acquired lives to drive efficiency and unlock embedded margin potential. Early results from Q3 2025 indicate this thesis is bearing fruit, with the company noting that Prospect’s standalone performance "exceeded expectations".
Astrana reports its financial and operational results through three synergistic segments that create a self-reinforcing flywheel:
Care Partners: This segment is the economic engine of the company, generating the vast majority of revenue ($897.7 million in Q3 2025, or roughly 94% of the total).
Care Delivery: While the Care Partners segment manages the financial risk, the Care Delivery segment provides the clinical boots on the ground. This segment includes Astrana’s primary care clinics, multi-specialty groups, and urgent care centers. It serves as a testing ground for clinical protocols and ensures that high-risk patients have access to accessible, culturally competent care.
Care Enablement: This segment provides the essential infrastructure that binds the network together. It includes the Management Services Organization (MSO) functions—such as billing, coding, credentialing, and compliance—and the proprietary technology stack. This segment allows Astrana to scale its network without a linear increase in administrative headcount.
As of January 9, 2026, Astrana Health trades on the NASDAQ Capital Market with a market capitalization of approximately $1.42 billion and an Enterprise Value (EV) approaching $2.0 billion.
The executive summary concludes that Astrana Health is a "Show Me" story that is rapidly transitioning into a "Showed You" story. The company has demonstrated it can grow profitably—a rarity in the VBC sector—and has a clear pathway to significant earnings expansion if it can successfully execute the operational turnaround of its acquired assets while navigating the headwinds of the Medicare Advantage regulatory environment.
To understand Astrana Health’s investment potential, one must first dissect the mechanics of its primary revenue driver: Capitation. In the traditional fee-for-service world, healthcare revenue is transactional and volume-dependent. A hospital or doctor is paid for each service performed, creating a perverse incentive to maximize utilization regardless of patient outcomes. Astrana flips this model.
The company enters into capitation agreements with health plans (payers) where it receives a fixed Per Member Per Month (PMPM) fee to manage the healthcare needs of a specific population. This shifts the financial risk from the insurance company to Astrana.
Global Risk: In its most advanced contracts (Global Risk), Astrana is responsible for the entire continuum of care, including primary care, specialist visits, and expensive institutional care like hospitalizations.
The Spread: The business model is essentially an arbitrage on medical efficiency. If Astrana receives $1,000 PMPM and can deliver high-quality outcomes for a medical cost of $850 PMPM, it retains the $150 spread as gross margin (Medical Margin).
The Flywheel Effect: As Astrana manages more lives, its data lake grows deeper. This enhanced data allows its CareOps platform to better predict patient risks and intervene earlier. Earlier intervention leads to lower medical costs (e.g., preventing a heart attack is cheaper than treating one). Lower costs lead to higher margins, which can be reinvested into better benefits for patients or higher payments for providers, attracting more of both and restarting the cycle.
The revenue mix has shifted decisively toward these risk-based arrangements. In the first half of 2025, capitation revenue represented the overwhelming majority of inflows, dwarfing fee-for-service revenue.
Astrana’s growth strategy for 2025 and beyond is built on three pillars: Inorganic Consolidation, Geographic Diversification, and Technological Enablement.
The acquisition of Prospect Health is the single largest driver of the company’s current financial profile. This deal was opportunistic, capitalizing on the distressed nature of Prospect’s operations to acquire significant scale at a favorable valuation.
Integration Progress: The Q3 2025 report indicates that the integration is proceeding ahead of schedule. "Prospect's performance exceeded our expectations, and integration is progressing well," noted CEO Brandon Sim.
Synergy Realization: The primary lever for value creation here is the reduction of medical variability. Prospect’s legacy network operated with higher utilization rates than Astrana’s historical norms. By implementing Astrana’s utilization management protocols and referral networks, the company expects to drive Prospect’s Medical Loss Ratio (MLR) down, expanding EBITDA margins.
Historically, Astrana (as Apollo Medical) was heavily concentrated in California, specifically serving the Asian-American demographic in the San Gabriel Valley. The strategic imperative for 2025-2026 is to nationalize the platform.
Provider HealthLink (PHL) Partnership: In late 2024, Astrana initiated a partnership with Provider HealthLink to enter the Georgia market, targeting 10,000 Medicare Advantage members for onboarding in H1 2025.
Texas and Beyond: Through the Prospect acquisition, Astrana gained a foothold in Texas and Connecticut, markets with different payer dynamics and regulatory environments. This diversification is critical for mitigating the risk of adverse regulatory changes in any single state (e.g., changes to California’s Medi-Cal program).
In a crowded field of VBC enablers, Astrana differentiates itself through its CareOps ecosystem. This is not merely an electronic health record (EHR) but a comprehensive operating system for value-based care.
Data Ingestion and AI: The platform ingests data from disparate sources—claims feeds from payers, clinical data from provider EHRs, lab results, and social determinants of health (SDOH) data. It uses artificial intelligence to synthesize this into a "Golden Record" for each patient.
Predictive Workflows: The true moat is in the application of this data. The system identifies "rising risk" patients—those who are stable today but show early warning signs of deterioration (e.g., a diabetic patient who has missed two prescription refills).
Actionability: Instead of just generating a report, CareOps triggers a workflow. A care coordinator is alerted to contact the patient, a pharmacist is tasked with reconciling medications, or a mobile clinic is dispatched. This "closed-loop" system is what allows Astrana to consistently beat medical cost benchmarks.
A critical, often overlooked business driver is the alignment of management and provider incentives. Unlike corporate VBC players that are run by financial engineers, Astrana has deep clinical DNA.
Executive Compensation Structure: As detailed in the 2025 proxy materials, executive compensation is heavily weighted toward performance. For the CEO and CFO, equity awards are split, with two-thirds being performance-based restricted stock units (PSUs) tied to specific Revenue ($2.3 Billion) and Adjusted EBITDA ($240 Million) targets for the 2024-2026 period.
Provider Incentives: Astrana’s model allows independent physicians to remain independent while sharing in the savings they generate. This "surplus sharing" model creates a powerful economic bond between the company and its network, reducing provider churn—a key killer of VBC economics.
The financial performance of Astrana Health over the 2024-2025 period reflects a company successfully executing a "step-change" in scale while maintaining operational discipline.
Revenue Growth: The revenue trajectory has been explosive.
Q3 2025 Total Revenue: $956.0 million, up 100% year-over-year from $478.7 million in Q3 2024.
YTD 2025 Total Revenue: $2.23 billion, up 63% from $1.37 billion in the prior year period.
Driver Analysis: The doubling of revenue in Q3 is primarily attributable to the Prospect Health acquisition. However, the organic business also contributed, with the Care Partners segment growing 97% to $897.7 million. This suggests that even without the acquisition, Astrana was experiencing robust demand for its risk-bearing services.
Profitability Profile: Astrana distinguishes itself from peers like Agilon Health (which reported negative EBITDA in comparable periods) by maintaining profitability during high growth.
Adjusted EBITDA: Q3 2025 Adjusted EBITDA reached $68.5 million, a 52% increase over the $45.2 million reported in Q3 2024.
EBITDA Margin: The implied EBITDA margin for Q3 2025 is approximately 7.2%. While this is healthy, it represents a compression from historical levels, which often exceeded 10%. This compression is the expected result of integrating the lower-margin Prospect assets. Management’s long-term guidance targets a return to margins in the 10% to 20% range as synergies are realized.
Net Income Dynamics: GAAP Net Income for Q3 2025 was a modest $0.4 million ($0.01 per share), down significantly from prior periods.
Table 3.1: Comparative Financial Highlights (in Millions, except EPS)
A fortress balance sheet has historically been a key differentiator for Astrana, allowing it to act as a consolidator during market downturns.
Cash Position: As of the most recent reporting (proxied by
Debt Profile: The company’s total debt stands at approximately $1.06 billion.
Receivables: A critical line item to monitor is "Receivables, net." As of H1 2025, receivables were $308 million on a pro-forma basis.
Valuing Astrana requires a nuanced approach that accounts for its hybrid nature—part insurance company, part tech platform, part provider group.
Current Valuation Metrics (Jan 9, 2026):
Price: ~$28.00
Market Cap: ~$1.42 Billion
Enterprise Value (EV): ~$2.0 Billion
EV / LTM EBITDA: ~10.0x
EV / LTM Revenue: 0.6x
Peer Comparison: The market currently ascribes a significant "complexity discount" or "conglomerate discount" to Astrana relative to its purest peers.
Privia Health (PRVA): Trades at 20.1x EV/EBITDA and 1.2x EV/Revenue.
Agilon Health (AGL): Trades at distressed levels (negative EBITDA, 0.0x EV/Revenue).
Alignment Healthcare (ALHC): Trades at 0.5x EV/Revenue.
Valuation Thesis: At 10x EBITDA, Astrana is priced for "no growth" or "execution failure." However, the company is growing revenue at 100% and EBITDA at 50%. This dislocation presents a classic Growth at a Reasonable Price (GARP) opportunity. If Astrana can simply maintain its current margin profile while integrating Prospect, the multiple should re-rate toward the 12x-15x range, driving significant shareholder returns.
The most significant idiosyncratic risk facing Astrana Health is its reliance on a single major customer. According to the 10-K and recent quarterly filings, "Payer A" accounted for 32.4% of the company’s net revenue in the first six months of 2025, and an alarming 38.9% of its receivables as of June 30, 2025.
Identity Speculation: While not explicitly named in every snippet, context clues from the California market suggest "Payer A" is likely a major commercial carrier such as Elevance Health (Anthem Blue Cross) or Blue Shield of California, given Astrana’s historical geographic footprint and commercial line of business.
Operational Leverage: This concentration gives Payer A immense leverage. In contract negotiations, Payer A could demand lower capitation rates, threatening to move its members to a competitor. A 5% rate cut from Payer A would have a disproportionate impact on Astrana’s bottom line, potentially wiping out the profitability of that entire book of business.
Counterparty Risk: While major insurers are generally solvent, operational disputes can freeze cash flow. The concentration of receivables (39%) means that a dispute over risk adjustment data or claims adjudication with this one payer could create a liquidity crisis for Astrana, necessitating a draw on its credit facilities.
The regulatory environment for Value-Based Care has become increasingly hostile, creating a headwind for the entire sector.
CMS-HCC Model V28: The Centers for Medicare & Medicaid Services (CMS) is phasing in the Version 28 Risk Adjustment Model. This model removes over 2,000 diagnosis codes (ICD-10) that CMS believes were being used by VBC companies to artificially inflate patient risk scores (and thus revenue).
Impact: For Astrana, this means that for the same patient population, revenue could optically decline unless the company’s providers document more bona fide clinical conditions that remain in the model. This puts pressure on the CareOps platform to identify valid, reimbursable diagnoses that were previously overlooked.
Star Ratings Volatility: Medicare Advantage plans receive Quality Bonus Payments (QBPs) if they achieve a 4-Star rating or higher. These bonuses often represent the entire profit margin for a health plan. Astrana relies on "Risk pool settlements and incentives"
The integration of Prospect Health is a massive logistical undertaking with significant execution risk.
Cultural Mismatch: Astrana is merging its physician-led, data-driven culture with Prospect’s legacy culture. If Prospect’s providers resist the adoption of Astrana’s utilization management protocols, the expected margin expansion will not materialize.
IT Migration: Migrating millions of patient records and thousands of providers onto the CareOps platform is fraught with technical risk. Data loss, billing interruptions, or claims processing errors during the migration could lead to provider dissatisfaction and churn.
Interest Rate Sensitivity: With ~$1 billion in debt on the balance sheet, Astrana is sensitive to the cost of capital. While the Fed may signal rate cuts, any resurgence in inflation that keeps rates "higher for longer" will sustain high interest expenses, suppressing Net Income and EPS.
Healthcare Labor Inflation: The "Care Delivery" segment operates physical clinics, making it exposed to wage inflation for nurses, medical assistants, and administrative staff. Continued labor shortages in the healthcare sector could drive up SG&A expenses, eroding the operational leverage gained from the acquisition.
To provide a comprehensive view of the potential investment outcomes, we have modeled three scenarios for Astrana Health’s performance through the year 2030. These scenarios are based on varying assumptions regarding organic growth, integration success, and valuation multiple expansion.
Starting Point (2025 Est): Revenue ~$3.16B (Analyst Consensus
Valuation Methodology: We utilize an EV/EBITDA multiple approach, as this is the standard for profitable healthcare services companies.
Narrative: Astrana successfully integrates Prospect Health, realizing synergies faster than expected. The CareOps platform effectively mitigates V28 headwinds. The company diversifies away from Payer A through rapid growth in Texas and Georgia.
Key Assumptions:
Revenue CAGR (2025-2030): 18%. (Aggressive share taking in new markets).
EBITDA Margin: Expands to 11% (Lower end of long-term guidance).
Exit Multiple: 15x EBITDA (Re-rates to "Quality Compounder" status).
2030 Financials: Revenue ~$7.2 Billion; EBITDA ~$790 Million.
Outcome: Share price appreciation driven by both earnings growth and multiple expansion.
Narrative: The integration is successful but takes time. Margins improve modestly but are capped by structural regulatory pressures (V28). Revenue grows at a healthy but slowing pace. Valuation remains constant.
Key Assumptions:
Revenue CAGR (2025-2030): 12%. (Market growth + modest share gains).
EBITDA Margin: Stabilizes at 8.5%.
Exit Multiple: 10x EBITDA (Current multiple holds).
2030 Financials: Revenue ~$5.5 Billion; EBITDA ~$470 Million.
Outcome: Share price tracks earnings growth; no multiple expansion.
Narrative: Medical cost trends spiral out of control due to aging demographics. Payer A aggressively cuts rates. The Prospect integration stalls, leading to provider churn. Debt service becomes a burden.
Key Assumptions:
Revenue CAGR (2025-2030): 5% (Inflation only).
EBITDA Margin: Compresses to 5% (Loss of efficiency).
Exit Multiple: 7x EBITDA (Distressed valuation).
2030 Financials: Revenue ~$4.0 Billion; EBITDA ~$200 Million.
Outcome: Significant value destruction.
Note: Implied Equity Value assumes Net Debt remains constant at ~$1.0B for conservatism, though in Bull/Base cases it would likely be paid down.
Probability-Weighted Target: (0.20 $190) + (0.50 $64) + (0.30 * $7) = $72.10 Implied 5-Year Upside: +157%
This analysis suggests a favorable risk/reward profile. The "Base Case" alone offers a potential double, validating the investment thesis at the current entry price of ~$28.
| Category | Rating (1-10) | Detailed Analysis |
| Management Alignment | 9/10 | Exceptional. The executive team, particularly the Sim family, has significant skin in the game. Executive compensation is structured with 2/3 of equity awards tied to rigorous performance metrics (Revenue & EBITDA targets), ensuring they only win if shareholders win. |
| Revenue Quality | 6/10 | Moderate. While the recurring nature of capitation is high-quality, the score is penalized heavily for the 32% concentration with "Payer A". |
| Market Position | 8/10 | Strong. Astrana dominates its niche of Asian-American centric care in California and is successfully translating this "culturally competent" model to other demographics. Its "Payer Agnostic" stance gives it a larger TAM than closed-model competitors. |
| Growth Outlook | 9/10 | Superior. Achieving 100% YoY revenue growth in a mature sector is remarkable. The pipeline for "tuck-in" IPA acquisitions and "asset-light" partnerships (like PHL in Georgia) provides a long runway for double-digit growth. |
| Financial Health | 7/10 | Good. Unlike the "zombie" companies in the VBC space (Cano, Babylon), Astrana is EBITDA positive and cash flow generative. The score is capped at 7 due to the elevated leverage (3.1x) following the Prospect deal. |
| Business Viability | 8/10 | High. The transition to Value-Based Care is a bipartisan policy imperative to save the Medicare Trust Fund. Astrana’s model of enabling this transition for independent doctors puts it on the right side of history. |
| Capital Allocation | 8/10 | Smart. The management team has shown discipline. They avoided the SPAC-mania overvaluation trap of 2021 and waited for valuations to crash before buying Prospect Health at a distressed price. This counter-cyclical allocation is a hallmark of good stewardship. |
| Analyst Sentiment | 8/10 | Bullish. Wall Street consensus is overwhelmingly positive, with price targets ranging from $36 to $54, significantly above the current trading price. Analysts view the post-earnings sell-off as an overreaction. |
| Profitability | 7/10 | Solid. Generating positive Adjusted EBITDA in a sector rife with losses is a key differentiator. The challenge now is translating that EBITDA into GAAP Net Income as integration costs subside. |
| Track Record | 8/10 | Reliable. The company has a history of conservative guidance and operational beats. The "exceeded expectations" performance of Prospect in Q3 2025 reinforces their operational credibility. |
Overall Weighted Score: 7.8 / 10
Astrana Health Inc. (ASTH) represents a compelling asymmetric investment opportunity for the discerning healthcare investor. The company stands as a "survivor" and "consolidator" in a Value-Based Care sector that has seen significant carnage over the past three years.
The Thesis in Brief:
Arbitrageur of Efficiency: Astrana is essentially an industrial platform for fixing broken healthcare assets. It acquires inefficient provider networks (like Prospect), applies its CareOps technology to reduce waste, and captures the resulting margin. This is a repeatable, scalable business model with a massive Total Addressable Market (TAM).
Valuation Disconnect: The market is currently pricing Astrana with a "fear discount" due to the general struggles of the VBC sector and specific worries about its payer concentration. At ~10x EBITDA, the market is ignoring the company's 100% growth rate and its clear path to margin expansion. A re-rating to a multiple consistent with its growth profile (15x-18x) would drive substantial upside.
Strategic Scarcity: Profitable, scaled, multi-state VBC platforms are rare assets. Astrana’s unique profile makes it a prime candidate for eventual acquisition by a major payer looking to vertically integrate, providing a "floor" to the valuation.
Recommendation: Investors should view Astrana as a core holding for exposure to the VBC theme. The current price of ~$28 offers a favorable entry point. While volatility is to be expected given the regulatory environment and payer concentration, the long-term fundamentals—driven by the demographic tidal wave of aging Americans and the inevitable shift to risk-based reimbursement—remain robust.
Date of Analysis: January 9, 2026 Current Price: ~$28.00
The technical setup for Astrana Health is currently in a "corrective" or "consolidation" phase.
200-Day Moving Average (MA): The stock recently crossed below its 200-day MA, which sits at approximately $29.52.
The "Death Cross": Traders should watch for a "Death Cross" (where the 50-day MA crosses below the 200-day MA). If this pattern forms, it could signal further downside pressure. Conversely, a quick reclamation of the $29.52 level would be a "Bear Trap" and a very bullish signal.
Resistance (The Ceiling): Immediate resistance is at the $29.50 - $30.00 zone (the broken 200-day MA). The stock will likely struggle to get through this level on the first attempt as trapped buyers look to exit.
Support (The Floor): Strong support has been established in the $26.50 - $27.00 range. This level corresponds to prior consolidation zones and represents a "value zone" where institutional buyers have stepped in previously. A break below $26.50 would expose the 52-week lows near $20.00.
Short Interest: Short interest stands at approximately 2.98 million shares, or roughly 5.95% of the float.
Days to Cover: With a days-to-cover ratio of ~6.0, there is potential for a "short squeeze" if the company releases positive news (e.g., a guidance hike). Short sellers would need a full week of buying to cover their positions, which could exacerbate any upward move.
Verdict: Neutral-Bearish Short Term / Bullish Medium Term. The stock is in the "penalty box" technically. It needs to digest the recent move and prove that the $26.50 support level will hold.
Bear Case: If the broader market weakens, ASTH could drift down to test $25.00.
Bull Case: A high-volume close above $30.00 changes the narrative.
Strategy: For long-term investors, the zone between $26.50 and $28.00 represents an accumulation zone. The technical damage (loss of the 200-day MA) is noted, but fundamentally driven investors should view this as a dislocation between price and value.
Disclaimer: This report is for informational purposes only and does not constitute financial advice. All investment involves risk, including the loss of principal.
View Astrana Health, Inc. (ASTH) stock page
Loading the interactive version of this report…